XJPX
9820
Market cap25mUSD
Oct 09, Last price
3,735.00JPY
1D
-1.19%
1Q
2.89%
Jan 2017
122.32%
Name
MT Genex Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MT Genex Corporation, along with its group of companies, serves as a specialist contractor for both new construction and refurbishment of homes and commercial premises throughout Japan. Its activities are structured across four primary divisions: Renovation Services, Parking Solutions, Facilities Upkeep & Management, and Insurance Brokering. The firm executes both interior and exterior building and property enhancement projects, offering comprehensive design and oversight for real estate developments. Additionally, it is responsible for the operation, administration, and leasing of parking areas, as well as the general management of real estate holdings. MT Genex also devises and proposes risk management strategies, encompassing a variety of non-life insurance offerings. Further expanding its portfolio, the company is engaged in real estate development, hotel operations, and the maintenance of electrical systems. Established in Tokyo, Japan, in 1945, MT Genex Corporation functions as a subsidiary of Mori Trust Co., Ltd.
Key people
Koji Nagano
Director of Administration, Director · since 2021
Nobuo Shinozaki
Director of Renewal Business, Director · since 2019
Hitoshi Suzuki
President, President of Subsidiary, Representative Director · since 2016
Masahiko Yabe
Director of Sales Planning, Director of Building Administration Business, Director · since 2021
Kazuyasu Abe
Independent Director · since 2022
Tomokazu Adachi
Independent Director · since 2017
Miyuki Fukuda
Independent Director · since 2022
Yoshio Inoue
Independent Director · since 2022
Independent Director · since 2022
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||